NCT06223074View on ClinicalTrials.gov

Improving the Treatment of Acute Relapses in Multiple Sclerosis Through Intranasal Methylprednisolone Administration

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

January 9, 2023

Primary Completion Date

February 25, 2026

Study Completion Date

July 5, 2026

Conditions
Multiple Sclerosis Relapsing RemittingTreatment
Interventions
OTHER

IV Methylprednisolone administration

Group 1 will receive 1g methylprednisolone IV for 3 or 5 days, according to the severity of the relapse

DRUG

Nasal Methylprednisolone (MT)

Group 2 will receive the dose intranasal equivalent to 1g of methylprednisolone for 3 or 5 days according to the severity of the relapse

Trial Locations (1)

14269

Instituto Nacional de Neurología y Neurocirugía, Mexico City

All Listed Sponsors
collaborator

Instituto Nacional de Neurología y Neurocirugía

UNKNOWN

lead

Universidad Nacional Autonoma de Mexico

OTHER